Yıl: 2023 Cilt: 34 Sayı: 4 Sayfa Aralığı: 427 - 432 Metin Dili: İngilizce DOI: 10.5152/tjg.2023.21954 İndeks Tarihi: 04-05-2023

Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains

Öz:
Background: The purpose of this study was to determine the antimicrobial status of stocked clinical Helicobacter pylori isolates by using antibiotic gradient test and subsequently identify the mutations that cause clarithromycin resistance by DNA sequencing. Turkey is a transition zone between Europe and Asia; therefore, we also aimed to show both continents’ mutations in Turkish isolates. Methods: One hundred forty-seven H. pylori isolates that had been stocked at −80°C between 1998 and 2008 were randomly selected and included in the study. Antibiotic susceptibility tests were performed using antibiotic gradient test for clarithromycin, amoxicillin, tetracycline, metronidazole, and levofloxacin. A polymerase chain reaction targeting the region of 23S rRNA gene domain V of H. pylori was performed and the mutations responsible for resistance against clarithromycin were defined by sequencing. Results: All of the tested isolates were found susceptible to amoxicillin and tetracycline. However, clarithromycin, metronidazole, and levofloxacin resistance were detected in 28.5% (42/147), 44.8% (66/147), and 23.1% (34/147) of the isolates, respectively. Point muta- tions were detected in 46 isolates (46/147, 31.2%). The majority of mutations were defined as A2143G (19/46, 41.3%), A2142G (14/46, 30.4%), and A2142C (7/46, 15.2%), respectively. T2188C, T2182C, G1949A, G1940A, and C1944T mutations were also identified in the isolates. Conclusion: In conclusion, the most common mutations associated with clarithromycin resistance in H. pylori have been identified as A2143G, A2142G, and A2142C which are the most frequently detected mutations in European countries. Same mutations and other mutations like T2182C have also been detected frequently in north-eastern countries and China. Since Turkey is a transition zone between Europe and Asia, Turkey might have strains that carry mutations found in both continents.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Liu C, Wang Y, Shi J, et al. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol. 2021;14:1756284821989177. [CrossRef]
  • 2. Malfertheiner P, Selgrad M, Wex T, et al. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. Lancet Gastroenterol Hepatol. 2018;3(10):698-707. [CrossRef]
  • 3. Bastos J, Peleteiro B, Barros R, et al. Sociodemographic determinants of prevalence and incidence of Helicobacter pylori infection in Portuguese adults. Helicobacter. 2013;18(6):413-422. [CrossRef]
  • 4. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514-533. [CrossRef]
  • 5. Zhang M, Zhou YZ, Li XY, et al. Seroepidemiology of Helicobacter pylori infection in elderly people in the Beijing region, China. World J Gastroenterol. 2014;20(13):3635-3639. [CrossRef]
  • 6. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, crosssectional, screening with the 13C-Urea breath test. BMC Public Health. 2013;13:1215. [CrossRef]
  • 7. Herardi R, Syam AF, Simadibrata M, et al. Comparison of 10-day course of triple therapy Versus 14-day course for eradication of Helicobacter pylori infection in an Indonesian population: double-blinded randomized clinical trial. Asian Pac J Cancer Prev. 2020;21(1):19-24. [CrossRef]
  • 8. Kocazeybek B, Sakli MK, Yuksel P, et al. Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance. J Med Microbiol. 2019;68(4):566-573. [CrossRef]
  • 9. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011;8(2):79-88. [CrossRef]
  • 10. Shinzaki S, Fujii T, Bamba S, et al. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intest Res. 2018;16(4):609-618. [CrossRef]
  • 11. Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017;14(7):383-384. [CrossRef]
  • 12. Shiotani A, Lu H, Dore MP, Graham DY. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017;84(4):310-318. [CrossRef]
  • 13. Garrido L, Toledo H. Novel genotypes in Helicobacter pylori involving domain V of the 23S rRNA gene. Helicobacter. 2007;12(5):505-509. [CrossRef]
  • 14. Taylor DE, Ge Z, Purych D, Lo T, Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother. 1997;41(12):2621-2628. [CrossRef]
  • 15. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother. 1996;40(2):477-480. [CrossRef]
  • 16. Fontana C, Favaro M, Minelli S, et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob Agents Chemother. 2002;46(12):3765-3769. [CrossRef]
  • 17. Caliskan R, Tokman HB, Erzin Y, et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop. 2015;48(3):278- 284. [CrossRef]
  • 18. Wilson K. Preparation of genomic DNA from bacteria. Curr Protoc Mol Biol. 2001;Chapter(2)(2):Unit 2.4. [CrossRef]
  • 19. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-239. [CrossRef]
  • 20. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. [CrossRef]
  • 21. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143-1153. [CrossRef]
  • 22. Cağdaş U, Otağ F, Tezcan S, Sezgin O, Aslan G, Emekdaş G. Detection of Helicobacter pylori and antimicrobial resistance in gastric biopsy specimens. Mikrobiyol Bul. 2012;46(3):398-409.
  • 23. Can F, Demirbilek M, Selçuk H, Arslan H, Boyacioğlu S. Clarithromycin resistance of Helicobacter pylori strains isolated from antral biopsy specimens. Mikrobiyol Bul. 2004;38(4):349-353.
  • 24. Kocazeybek B, Tokman HB. Prevalence of primary antimicrobial resistance of H. pylori in Turkey: a systematic review. Helicobacter. 2016;21(4):251-260. [CrossRef]
  • 25. Yula E, Nagiyev T, Kaya OA, Inci M, Celik MM, Köksal F. Detection of primary clarithromycin resistance of Helicobacter pylori and association between cagA (+) status and clinical outcome. Folia Microbiol (Praha). 2013;58(2):141-146. [CrossRef]
  • 26. Kalem F, Özdemir M, Başaranoğlu M, Toy H, Baysal B. Helicobacter pylori isolates recovered from antral gastric biopsies of patients With dyspeptic symptoms: antimicrobial resistance of metronidazole, clarithromycin and amoxicillin. Anatol J Clin Investig. 2012;6:238-241.
  • 27. Bakir Ozbey S, Ozakin C, Keskin M. Antibiotic resistance rates of Helicobacter pylori isolates and the comparison of E-test and fluorescent in situ hybridization methods for the detection of clarithromycin resistant strains. Mikrobiyol Bul. 2009;43(2): 227-234.
  • 28. Erkut M, Uzun DY, Kaklıkkaya N, et al. Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the eastern Black Sea region of Turkey. Turk J Gastroenterol. 2020;31(3):221-233. [CrossRef]
  • 29. Seo SI, Do BJ, Kang JG, et al. Helicobacter pylori eradication according to sequencing-based 23S ribosomal RNA point mutation associated with clarithromycin resistance. J Clin Med. 2019;9(1). [CrossRef]
  • 30. Kim JM, Kim JS, Kim N, et al. Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. J Microbiol Biotechnol. 2008;18(9):1584-1589.
  • 31. Vianna JS, Ramis IB, Ramos DF, VON Groll A, Silva PE. Drug resistance in Helicobacter pylori. Arq Gastroenterol. 2016;53(4):215-223. [CrossRef]
  • 32. Raymond J, Burucoa C, Pietrini O, et al. Clarithromycin resistance in Helicobacter pylori strains isolated from French children: prevalence of the different mutations and coexistence of clones harboring two different mutations in the same biopsy. Helicobacter. 2007;12(2):157-163. [CrossRef]
  • 33. Agudo S, Pérez-Pérez G, Alarcón T, López-Brea M. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol. 2010;48(10):3703-3707. [CrossRef]
  • 34. Park CG, Kim S, Lee EJ, Jeon HS, Han S. Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication: a prospective, observational study. Med (Baltim). 2018;97(33):e11835. [CrossRef]
  • 35. Kim KS, Kang JO, Eun CS, Han DS, Choi TY. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. J Korean Med Sci. 2002;17(5):599-603. [CrossRef]
  • 36. Alavifard H, Mirzaei N, Yadegar A, et al. Investigation of clarithromycin resistance-associated mutations and virulence genotypes of Helicobacter pylori isolated from Iranian population: a cross-sectional study. Curr Microbiol. 2021;78(1):244-254. [CrossRef]
  • 37. Chu A, Wang D, Guo Q, Lv Z, Yuan Y, Gong Y. Molecular detection of H. pylori antibiotic-resistant genes and molecular docking analysis. FASEB J. 2020;34(1):610-618. [CrossRef]
APA Örsten S, Yilmaz E, AKYON YILMAZ Y (2023). Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. , 427 - 432. 10.5152/tjg.2023.21954
Chicago Örsten Serra,Yilmaz Engin,AKYON YILMAZ YAKUT Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. (2023): 427 - 432. 10.5152/tjg.2023.21954
MLA Örsten Serra,Yilmaz Engin,AKYON YILMAZ YAKUT Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. , 2023, ss.427 - 432. 10.5152/tjg.2023.21954
AMA Örsten S,Yilmaz E,AKYON YILMAZ Y Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. . 2023; 427 - 432. 10.5152/tjg.2023.21954
Vancouver Örsten S,Yilmaz E,AKYON YILMAZ Y Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. . 2023; 427 - 432. 10.5152/tjg.2023.21954
IEEE Örsten S,Yilmaz E,AKYON YILMAZ Y "Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains." , ss.427 - 432, 2023. 10.5152/tjg.2023.21954
ISNAD Örsten, Serra vd. "Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains". (2023), 427-432. https://doi.org/10.5152/tjg.2023.21954
APA Örsten S, Yilmaz E, AKYON YILMAZ Y (2023). Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. Turkish Journal of Gastroenterology, 34(4), 427 - 432. 10.5152/tjg.2023.21954
Chicago Örsten Serra,Yilmaz Engin,AKYON YILMAZ YAKUT Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. Turkish Journal of Gastroenterology 34, no.4 (2023): 427 - 432. 10.5152/tjg.2023.21954
MLA Örsten Serra,Yilmaz Engin,AKYON YILMAZ YAKUT Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. Turkish Journal of Gastroenterology, vol.34, no.4, 2023, ss.427 - 432. 10.5152/tjg.2023.21954
AMA Örsten S,Yilmaz E,AKYON YILMAZ Y Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. Turkish Journal of Gastroenterology. 2023; 34(4): 427 - 432. 10.5152/tjg.2023.21954
Vancouver Örsten S,Yilmaz E,AKYON YILMAZ Y Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. Turkish Journal of Gastroenterology. 2023; 34(4): 427 - 432. 10.5152/tjg.2023.21954
IEEE Örsten S,Yilmaz E,AKYON YILMAZ Y "Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains." Turkish Journal of Gastroenterology, 34, ss.427 - 432, 2023. 10.5152/tjg.2023.21954
ISNAD Örsten, Serra vd. "Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains". Turkish Journal of Gastroenterology 34/4 (2023), 427-432. https://doi.org/10.5152/tjg.2023.21954